In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This study cohort was made up of 71.3% U.K. patients ...

Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

Sometimes signs of chronic and serious diseases can show up in the most unexpected ways and places. One such condition is Bronchiectasis. It is a chronic lung condition that damages your airways, ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...

The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion Inc., a biopharmaceutical company focused on developing therapies to restore lung health in individuals with mucus-related lung diseases, announced topline ...